Ikena Oncology Stock News

Ikena Oncology, Inc. (NASDAQ:IKNA) traded down 7.6% during mid-day trading on Friday . The stock traded as low as $14.42 and last traded at $14.42. 2,532 shares were traded during mid-day trading, a decline of 98% from the average session volume of 146,454 shares. The stock had previously closed at $15.61. Several analysts have recently […]

Ikena Oncology, Inc. (NASDAQ:IKNA) shares traded up 11.4% on Tuesday . The stock traded as high as $14.34 and last traded at $13.99. 4,337 shares were traded during trading, a decline of 97% from the average session volume of 146,011 shares. The stock had previously closed at $12.56. Several equities analysts have recently weighed in []

Nuveen Asset Management LLC bought a new position in Ikena Oncology, Inc. (NASDAQ:IKNA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 27,055 shares of the companys stock, valued at approximately $379,000. Nuveen Asset Management LLC owned about 0.08% of Ikena []

Ikena Oncology, Inc. (NASDAQ:IKNA)s share price was up 7.1% during mid-day trading on Wednesday . The stock traded as high as $13.95 and last traded at $13.95. Approximately 1,439 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 146,593 shares. The stock had previously closed at $13.03. Several []

Ikena Oncology (NASDAQ:IKNA) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The companys product candidates include IK-930, []

Ikena Oncology, Inc. (NASDAQ:IKNA) Analysts at William Blair decreased their FY2021 earnings estimates for shares of Ikena Oncology in a report issued on Wednesday, November 10th. William Blair analyst M. Phipps now expects that the company will post earnings per share of ($1.91) for the year, down from their previous estimate of ($1.76). William []

Ikena Oncology (NASDAQ:IKNA) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued on Tuesday, Zacks.com reports. According to Zacks, Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The companys product candidates include []

BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced t

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three abs

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announc

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of